7月9日 - ** 制药商Rhythm Pharmaceuticals RYTM.O股价盘前上涨15.14%至75美元
** 该公司在一项由28名12岁或12岁以上患者参加的中期试验中测试了 (link)。
** 在对获得性下丘脑肥胖症患者进行 14 周的治疗后，该药物显示体重指数有所下降
** 公司计划就后期试验设计征求美国和欧盟监管机构的意见
** 获得性下丘脑肥胖症是一种罕见的肥胖症，是大脑下丘脑区域受损后出现的肥胖症
** 截至上一交易日收盘，股价累计上涨约 16
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.